Andrew Dickinson compensation by year
GILEAD SCIENCES Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $802,308 | $986,538 | $973,567 | $1,018,419 | $1,052,396 | $1,083,969 | $1,116,654 |
| Bonus | $1,000,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $1,708,267 | $2,260,949 | $2,862,493 | $3,992,603 | $4,143,271 | $4,080,024 | $4,321,741 |
| Option awards | $1,000,096 | $874,968 | $1,049,984 | $1,474,983 | $1,299,966 | $1,300,029 | $1,299,976 |
| Non-equity incentive | $1,086,800 | $1,704,300 | $1,558,751 | $1,885,572 | $1,574,304 | $1,608,840 | $1,956,266 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $12,000 | $15,000 | $15,000 | $31,121 | $37,886 | $36,896 | $70,979 |
| Total | $5,609,471 | $5,841,755 | $6,459,795 | $8,402,698 | $8,107,823 | $8,109,758 | $8,765,616 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GILEAD SCIENCES, INC. DEF 14A filed March 20, 2026, accession 0001308179-26-000106, and prior-year filings.
How this page was built: the GILEAD SCIENCES, INC. filed document, accession 0001308179-26-000106. Every figure is read from that document and cited to the page and table it appears in. Filed March 20, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 29,670 | $3,641,696 | — |
| PSU | 18,450 | $2,264,553 | — |
| RSU | 11,090 | $1,361,187 | — |
| RSU | 10,176 | $1,248,991 | — |
| RSU | 9,734 | $1,194,751 | — |
| RSU | 9,615 | $1,180,132 | — |
| RSU | 7,787 | $955,752 | — |
| PSU | 7,440 | $913,186 | — |
| RSU | 7,432 | $912,157 | — |
| RSU | 7,358 | $903,060 | — |
| RSU | 5,110 | $627,201 | — |
| RSU | 1,592 | $195,402 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in GILEAD SCIENCES, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 16 award rows shown.
Insider transactions since the last proxy
13 Form 4 lines since the FY2025 proxy (filed March 20, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-15 | Sale | 10b5-1 | 3,000 | $156.22 | 161,096 |
| 2026-09-15 | Sale | 10b5-1 | 3,000 | $145.29 | 164,096 |
| 2026-09-10 | Exercise or conversion | — | 2,797 | — | 168,443 |
| 2026-09-10 | Tax withholding | — | 1,347 | $144.81 | 167,096 |
| 2026-09-10 | Exercise or conversion derivative | — | 2,797 | — | 25,054 |
| 2026-08-17 | Sale | 10b5-1 | 3,000 | $138.36 | 165,646 |
| 2026-07-15 | Sale | 10b5-1 | 3,000 | $129.93 | 168,646 |
| 2026-06-15 | Sale | 10b5-1 | 3,000 | $125.40 | 171,646 |
The 8 most recent of 13 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
GILEAD SCIENCES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel O'Day | Chairman and Chief Executive Officer | $28,437,198 |
| Dietmar Berger | Chief Medical Officer | $13,922,878 |
| Johanna Mercier | Chief Commercial and Corporate Affairs Officer | $9,300,643 |
| Andrew Dickinson · this page | Chief Financial Officer | $8,765,616 |
| Deborah Telman | Former Executive Vice President, Corporate Affairs and General Counsel | $5,004,669 |
Andrew Dickinson's compensation dossier, GILEAD SCIENCES
You have read Andrew Dickinson's totals and holdings. The dossier adds each equity grant GILEAD SCIENCES disclosed for Andrew Dickinson and GILEAD SCIENCES's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full GILEAD SCIENCES compensation record
free company briefThis page is one person within GILEAD SCIENCES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the GILEAD SCIENCES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order GILEAD SCIENCES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GILEAD SCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.